drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Antibody-drug conjugate targeting a tumor-associated cell-surface antigen; internalizes and releases a cytotoxic payload (e.g., topoisomerase I or microtubule-targeting warhead) to kill cancer cells.
nci_thesaurus_concept_id
C200198
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) conjugated, via a cleavable linker, to a topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-nectin-4 ADC SHR-A2102 targets and binds to nectin-4 expressed on tumor cells. Upon binding, internalization and linker cleavage, topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing nectin-4. Nectin-4 is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
IgG1 monoclonal antibody targeting nectin‑4 binds tumor cells, is internalized, and via a cleavable linker releases a topoisomerase I inhibitor payload that blocks DNA topoisomerase I, inhibiting DNA replication and inducing cell-cycle arrest and apoptosis in nectin‑4–expressing cancers.
drug_name
SHR-A2102
nct_id_drug_ref
NCT06547736